Clinical Trials Browser

Non-Small Cell Lung Cancer Metastatic × patritumab deruxtecan × 90 days × Clear all

NCT04619004 2026-01-23

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

277 enrolled 16 charts

Non-Small Cell Lung Cancer Metastatic